FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc_20100128
Regeneron Pharmaceuticals Inc_20131212

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Regeneron Pharmaceuticals, Inc. patents


      
Recent patent applications related to Regeneron Pharmaceuticals, Inc.. Regeneron Pharmaceuticals, Inc. is listed as an Agent/Assignee. Note: Regeneron Pharmaceuticals, Inc. may have other listings under different names/spellings. We're not affiliated with Regeneron Pharmaceuticals, Inc., we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "R" | Regeneron Pharmaceuticals, Inc.-related inventors



Search recent Press Releases: Regeneron Pharmaceuticals, Inc.-related press releases
Count Application # Date Regeneron Pharmaceuticals, Inc. patents (updated weekly) - BOOKMARK this page
12015002441201/22/15Humanized fcgammar mice
22015001717601/15/15Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
32015001718201/15/15Methods for treating nasal polyposis by administering an il-4r antagonist
42015002022401/15/15Non-human animals with modified immunoglobulin heavy chain sequences
52015001056801/08/15Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
62015001302201/08/15Humanized il-6 and il-6 receptor
72015001302301/08/15Humanized il-6 and il-6 receptor
82014035637012/04/14Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations
92014035637112/04/14Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
102014035637212/04/14Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
112014033134011/06/14Methods and compositions for generating a mouse
122014032221510/30/14Methods of inhibiting tumor growth by antagonizing il-6 receptor
132014031524910/23/14Inducible eukaryotic expression system
142014028987609/25/14Mice that make heavy chain antibodies
152014027164209/18/14Il-33 antagonists and uses thereof
162014027165309/18/14Human antibodies to respiratory syncytial virus f protein and methods of use thereof
172014027165809/18/14Anti-il-33 antibodies and uses thereof
182014027168109/18/14High affinity human antibodies to human il-4 receptor
192014027309509/18/14Serum-free cell culture medium
202014027548909/18/14Apelin fusion proteins and uses thereof
212014028315809/18/14Rodents with conditional acvr1 mutant alleles
222014025539009/11/14Method of treating rheumatoid arthritis with an anti-il-6r antibody
232014025541909/11/14Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
242014025542909/11/14Methods of treating autoimmune diseases with dll4 antagonists
252014025599509/11/14High affinity antibodies to human il-6 receptor
262014024866409/04/14Readily isolated bispecific antibodies with native immunoglobulin format
272014024350408/28/14Antibodies comprising chimeric constant domains
282014024546608/28/14Humanized t cell co-receptor mice
292014024546708/28/14Genetically modified major histocompatibility complex mice
302014024546808/28/14Non-human animals with modified immunoglobulin heavy chain sequences
312014022002308/07/14Method of treating osteoarthritis with an antibody to ngf
322014021377307/31/14Adam6 mice
332014019655007/17/14Systems and devices for sample handling
342014019976107/17/14Promoter-regulated differentiation-dependent self-deleting cassette
352014019340207/10/14Anti-pdgfr-beta antibodies and uses thereof
362014019459707/10/14Modified chimeric polypeptides with improved pharmacokinetic properties
372014018990007/03/14Mirna-regulated differentiation-dependent self-deleting cassette
382014017887906/26/14Compositions and methods for modifying cells
392014017990306/26/14High affinity human antibodies to human protease-activated receptor 2
402014015470106/05/14Humanized fc gamma r mice
412014015568906/05/14Methods of modifying genes in eukaryotic cells
422014015744506/05/14Low affinity fcgr deficient mice
432014013797805/22/14System and methods for use in dispensing biopharmaceutical materials
442014013416905/15/14Methods of treating ovarian cancer with dll4 antagonists
452014013418905/15/14Anti-prokineticin receptor (prokr) antibodies and uses thereof
462014013471905/15/14Recombinant cell surface capture proteins
472014013727505/15/14Hybrid light chain mice
482014013019305/08/14Mice that make vl binding proteins
492014013019405/08/14Mice that make vl binding proteins
502014012010905/01/14Human antibodies to human tnf-like ligand 1a (tl1a)
512014011293004/24/14Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
522014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
532014008829503/27/14Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
542014008276003/20/14Non-human animals expressing ph-sensitive immunoglobulin sequences
552014007256303/13/14Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
562014007258303/13/14Methods for treating atopic dermatitis by administering an il-4r antagonist
572014007297903/13/14Isolating cells expressing secreted proteins
582014007298003/13/14Isolating cells expressing secreted proteins
592014007301003/13/14Methods of modifying eukaryotic cells
602014007558603/13/14Parental cell lines for making cassette-free f1 progeny
612014005690302/27/14Human antibodies to gfr alpha 3 and methods of use thereof
622014005690702/27/14Anti-asic1 antibodies and uses thereof
632014004473002/13/14Anti-pcsk9 antibodies with ph-dependent binding characteristics
642014004106802/06/14Methods of modifying eukaryotic cells
652014003333601/30/14Methods of modifying eukaryotic cells
662014003333701/30/14Methods of modifying eukaryotic cells
672014002363701/23/14Methods of modifying eukaryotic cells
682014001722801/16/14Humanized light chain mice
692014001722901/16/14Methods of modifying eukaryotic cells
702014001723801/16/14Methods of modifying eukaryotic cells
712014001769501/16/14Isolating cells expressing secreted proteins
722014001778101/16/14Methods of modifying eukaryotic cells
732014001778201/16/14Methods for modifying eukaryotic cells
742014001852201/16/14Methods of modifying eukaryotic cells
752014002012401/16/14Methods of modifying eukaryotic cells
762014002012501/16/14Methods of modifying eukaryotic cells
772014001345601/09/14Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
782014001345701/09/14Methods of modifying eukaryotic cells
792013034453812/26/13Human antibodies to the glucagon receptor
802013034010412/19/13Humanized il-7 rodents
812013033305712/12/13Humanized non-human animals with restricted immunoglobulin heavy chain loci
822013032326012/05/13Stabilized formulations containing anti-dll4 antibodies
832013032326112/05/13Purified antibody composition
842013032378812/05/13Production cell line enhancers
852013032379012/05/13Human lambda light chain mice
862013032379112/05/13Restricted immunoglobulin heavy chain mice
872013032664712/05/13Human lambda light chain mice
882013030967011/21/13Nuclease-mediated targeting with large targeting vectors
892013031212811/21/13Promoter-regulated differentiation-dependent self-deleting cassette
902013031212911/21/13Promoter-regulated differentiation-dependent self-deleting cassette
912013029509711/07/13Human antibodies to fel d1 and methods of use thereof
922013028075810/24/13Fusion polypeptides capable of activating receptors
932013027307010/17/13Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
942013026657410/10/13Human antibodies to human angiopoietin-like protein 4
952013025987610/03/13Anti-hla-b*27 antibodies and uses thereof
962013025988110/03/13Fusion polypeptides capable of activating receptors
972013026105610/03/13Vegf antagonist formulations
982013025172809/26/13Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
992013025491109/26/13Adam6 mice
1002013024377509/19/13Multispecific antigen-binding molecules and uses thereof
1012013024378409/19/13Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
1022013024723409/19/13Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
1032013024723509/19/13Mice that produce antigen-binding proteins with ph-dependent binding characteristics
1042013024723609/19/13Non-human animals expressing ph-sensitive immunoglobulin sequences
1052013023053109/05/13Human antibodies to clostridium difficile toxins
1062013023053309/05/13Methods of treating systemic lupus erythematosus (sle) using anti-cd48 antibodies
1072013021654708/22/13Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
1082013020949208/15/13Anti-tie2 antibodies and uses thereof
1092013021013708/15/13Methods of modifying eukaryotic cells
1102013021271908/15/13Humanized rodents that express heavy chain containing vl domains
1112013019587808/01/13Anti-asic1 antibodies and uses thereof
1122013019887908/01/13Humanized universal light chain mice
1132013019888008/01/13Mice expressing a limited immunoglobulin light chain repertoire
1142013018679707/25/13Stabilized formulations containing anti-ang2 antibodies
1152013018927707/25/13Stabilized formulations containing anti-pcsk9 antibodies
1162013018420507/18/13Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
1172013018581907/18/13Genetically modified major histocompatibility complex animals
1182013018582007/18/13Genetically modified major histocompatibility complex animals
1192013018582107/18/13Common light chain mouse
1202013017114907/04/13Anti-angptl3 antibodies and uses thereof
1212013016478606/27/13Fucosylation-deficient cells
1222013015731306/20/13High affinity antibodies to human il-6 receptor
1232013016015306/20/13Humanized light chain mice
1242013014974406/13/13Methods for producing a fusion protein capable of binding vegf
1252013013710105/30/13Methods of modifying eukaryotic cells
1262013012972205/23/13Methods for treating cancer by administering an anti-ang-2 antibody
1272013012983005/23/13Polymer protein microparticles
1282013013037205/23/13Enhanced expression and stability regions
1292013013038805/23/13Methods of modifying eurakyotic cells
1302013012200305/16/13Methods of inhibiting tumor growth by antagonizing il-6 receptor
1312013012200705/16/13Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
1322013011787305/09/13Humanized il-6 and il-6 receptor
1332013010905305/02/13Genetically modified t cell receptor mice
1342013011161605/02/13Genetically modified major histocompatibility complex mice
1352013011161705/02/13Genetically modified major histocompatibility complex mice
1362013009556504/18/13Mirna-regulated differentiation-dependent self-deleting cassette
1372013009628704/18/13Restricted immunoglobulin heavy chain mice
1382013008429704/04/13Anti-erbb3 antibodies and uses thereof
1392013008463504/04/13Cell culture compositions capable of producing a vegf-binding fusion polypeptide
1402013008526604/04/13Anti-pcsk9 antibodies with ph-dependent binding characteristics
1412013007867503/28/13High affinity human antibodies to human il-4 receptor
1422013006483403/14/13Methods for treating hypercholesterolemia using antibodies to pcsk9
1432013004549202/21/13Methods for making fully human bispecific antibodies using a common light chain
1442013003490202/07/13Fusion polypeptides capable of activating receptors
1452013002889201/31/13Method of treating osteoarthritis with an antibody to ngf
1462012032210812/20/12Adam6 mice
1472012032349712/20/12Non-hypergeometric overlap probability
1482012025809810/11/12Method of treating rheumatoid arthritis with an anti-il-6r antibody
1492012026035710/11/12Low affinity fcgr deficient mice
1502012019589608/02/12Igf-1 fusion polypeptides and therapeutic uses thereof
1512012018963507/26/12Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
1522012019230007/26/12Common light chain mouse
1532012017868307/12/12Vegf antagonist formulations
1542012016468806/28/12High affinity human antibodies to human nerve growth factor
1552012013501005/31/12High affinity human antibodies to human il-4 receptor
1562012012867905/24/12Human antibodies to the glucagon receptor
1572012011464505/10/12Use of il-1 antagonists to treat pseudogout
1582012011465405/10/12Human antibodies to human tnf-like ligand 1a (tl1a)
1592012011466505/10/12Human antibodies to human rankl
1602012009756504/26/12Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
1612012010014504/26/12Methods for treating b-cell lymphoma by administering an anti-cd20 antibody
1622012010103504/26/12Vegf antagonist formulations
1632012009382404/19/12Methods for treating pruritus by administering an antibody that specifically binds human par2
1642012009657204/19/12Mice that make vl binding proteins
1652012008792904/12/12Vegf antagonist formulations for intravitreal administration
1662012008300004/05/12Neuropeptide release assay for sodium channels
1672012007679003/29/12Anti-cd48 antibodies and uses thereof
1682012007086103/22/12Human lambda light chain mice
1692012007300403/22/12Hybrid light chain mice
1702012006462103/15/12Cell culture compositions capable of producing a vegf-binding fusion polypeptide
1712012005207203/01/12High affinity human antibodies to human il-4 receptor
1722012004544002/23/12Method of treating rheumatoid arthritis with an anti-il-6r antibody
1732012002140901/26/12Common light chain mouse
1742012001496801/19/12Stabilized formulations containing anti-ngf antibodies
1752012000369701/05/12High affinity antibodies to human il-6 receptor
1762011031834212/29/11Methods of using il-1 antagonists to treat autoinflammatory disease
1772011031153712/22/11Methods of using il-1 antagonists to treat familial mediterranean fever (fmf)
1782011030796612/15/11Mice expressing human voltage-gated sodium channels
1792011030796812/15/11Production of fertile xy animals from xy es cells
1802011029363012/01/11Antibodies to human gdf8
1812011028337611/17/11Methods of modifying eukaryotic cells
1822011026918711/03/11High affinity human antibodies to human il-18 receptor
1832011025614810/20/11Methods for treating hypercholesterolemia using antibodies to pcsk9
1842011025655610/20/11Humanized fcgr mice
1852011025658710/20/11High affinity human antibodies to human nerve growth factor
1862011025760110/20/11Vegf antagonist formulations for intravitreal administration
1872011025871010/20/11Methods of modifying eukaryotic cells
1882011019545408/11/11Common light chain mouse
1892011018917608/04/11Methods of treating diseases with dll4 antagonists
1902011018920008/04/11Methods of treating autoimmune diseases with dll4 antagonists
1912011017124107/14/11Stabilized formulations containing anti-interleukin-6 (il-6) antibodies
1922011016565007/07/11Fusion polypeptides capable of activating receptors
1932011015901506/30/11Human antibodies to human angiopoietin-like protein 4
1942011015090506/23/11Human antibodies to human delta like ligand 4
1952011015451206/23/11Humanized fc gamma r mice
1962011014593706/16/11Mice that make heavy chain antibodies
1972011010479905/05/11Multifunctional alleles
1982011008168104/07/11Human antibodies to human cd20 and using thereof
1992011006590203/17/11High affinity human antibodies to pcsk9
2002011005909503/10/11High affinity human antibodies to human protease-activated receptor-2
2012011004119602/17/11Mirna-regulated differentiation-dependent self-deleting cassette
2022011004119702/17/11Promoter-regulated differentiation-dependent self-deleting cassette
2032011002728602/03/11High affinity human antibodies to human angiopoietin-2
2042011002034201/27/11Igf-1 fusion polypeptides and therapeutic uses thereof
2052011001420801/20/11Method of treating osteoarthritis with an antibody to ngf
2062011000837401/13/11Use of il-1 antagonists to treat gout
2072010033010612/30/10Method of treating cancer with dll4 antagonist and chemotherapeutic agent
2082010033152712/30/10Readily isolated bispecific antibodies with native immunoglobulin format
2092010031662712/16/10Human antibodies to human il-6 receptor
2102010031663612/16/10Method of treating rheumatoid arthritis with an il-6r antibody
2112010030443612/02/10Fucosylation-deficient cells
2122010029110711/18/10High affinity human antibodies to human il-4 receptor
2132010029162611/18/10Enhanced expression and stability regions
2142010027993311/04/10Vegf antagonist formulations
2152010023380309/16/10Fusion polypeptides capable of activating receptors
2162010022178209/02/10Modified chimeric polypeptides with improved pharmacokinetic properties
2172010016676807/01/10High affinity human antibodies to pcsk9
2182010012981705/27/10Identifying germline competent embryonic stem cells
2192010011192105/06/10Use of il-1 antagonists to treat gout
2202010008763204/08/10Vegf-binding fusion proteins and therapeutic uses thereof
2212010007590303/25/10Lyophilized vegf antagonist formulations for intravitreal administration
2222010004725402/25/10High affinity human antibodies to human il-4 receptor
2232010004233002/18/10Non-hypergeometric overlap probability
2242010003483302/11/10High affinity human antibodies to human il-18 receptor
2252010002147601/28/10High affinity human antibodies to human il-4 receptor
2262009028584111/19/09Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
2272009027188410/29/09Es cell-derived mice from diploid host embryo injection
2282009024619910/01/09Therapeutic methods for inhibiting tumor growth with dll4 antagonists
2292009017586407/09/09Igf-1 and igf-2 chimeric polypeptides and therapeutic uses thereof
2302009016290106/25/09Inducible eukaryotic expression system
2312009015589906/18/09Modified chimeric polypeptides with improved pharmacokinetic properties
2322009015649206/18/09Methods of using il-1 antagonists to treat autoinflammatory disease
2332009014235406/04/09Human antibodies to human delta like ligand 4
2342009013741605/28/09Isolating cells expressing secreted proteins
2352009012344605/14/09Use of il-1 antagonists to treat gout
2362009012400505/14/09Enhanced expression and stability regions
2372009008121703/26/09Modified chimeric polypeptides with improved pharmacokinetic properties
2382009007479303/19/09High affinity human antibodies to human il-4 receptor
2392009006220003/05/09Vegf-binding fusion proteins and therapeutic uses thereof
2402009003532202/05/09Human antibodies to human cd20 and using thereof
2412013033305712/12/13Humanized non-human animals with restricted immunoglobulin heavy chain loci
2422010002147601/28/10High affinity human antibodies to human il-4 receptor


ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Regeneron Pharmaceuticals, Inc. in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Regeneron Pharmaceuticals, Inc. with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE